現在販売されている主なGLP-1製剤として、Eli Lilly社のDulaglutide（商品名Trulicity）、Tirzepatide（商品名Mounjaro, Zepbound）、Novo Nordisk社のLiraglutide（商品名Victoza, Saxenda）、Semaglutide（商品名Ozempic, Wegovy, Rybelsus）があります。

Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are ...

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide ...

Every January, millions of people start the new year vowing to lose weight. But in 2025, many of those hoping to shed the ...

IT’S become one of the most popular ways in the showbiz world to stay slim. But Katherine Ryan has hit back at claims she’s ...

The growing popularity of GLP-1 receptor agonists—including Ozempic and Wegovy from Novo Nordisk, and Mounjaro and Zepbound ...

Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...

Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...

Alabama now provides partial GLP-1 coverage for obesity: Among the obesity-indicated GLP-1s, Medicaid in Alabama covers just ...

In these states, beneficiaries have access to Wegovy, Zepbound, and Saxenda, alongside Type 2 diabetes-indicated options such ...

In these states, beneficiaries have access to Wegovy, Zepbound, and Saxenda, alongside Type 2 diabetes-indicated options such ...